Literature DB >> 18324493

Molecular epidemiology and antifungal susceptibility patterns of Sporothrix schenckii isolates from a cat-transmitted epidemic of sporotrichosis in Rio de Janeiro, Brazil.

Maria Clara Gutierrez Galhardo1, Rosely Maria Zancopé De Oliveira, Antonio Carlos Francesconi Do Valle, Rodrigo De Almeida Paes, Patricia Morais E Silvatavares, Araceli Monzon, Emilia Mellado, Juan L Rodriguez-Tudela, Manuel Cuenca-Estrella.   

Abstract

Since 1998 a cat-transmitted epidemic of sporotrichosis has been observed in Rio de Janeiro (RJ), Brazil. Besides the lymphocutaneous and fixed forms, other presentations, such as disseminated cutaneous and mucosal involvement, as well as for the first time, erythema nodosum and erythema multiforme have been reported associated with sporotrichosis. This study investigates the phenotypes and genotypes of Sporothrix schenckii isolates recovered from different clinical forms of the disease noted as part of this epidemic. A total of 88 isolates recovered from 59 cases associated with the epidemic and 29 controls (from cases in other Brazilian regions and Spain) were included in this study. In vitro susceptibility testing was conducted as part of the phenotypic analysis, while the genotypic analysis involved a DNA fingerprinting method with primer M13 and ribosomal DNA sequencing of the internal transcribed spacer (ITS). MIC values of amphotericin B, itraconazole, posaconazole, ravuconazole, and terbinafine were found to be significantly lower (P<0.01) for isolates associated with the epidemic than for control strains. No differences in MIC values were observed related to clinical forms of the infection. Fingerprinting analysis showed that RJ epidemic strains were genetically related. Although nine subtypes were found, they were not associated with specific clinical forms. Similar results were obtained with the ITS sequence analysis. These data suggest that the strains isolated from the epidemic cases of sporotrichosis in RJ all originated from a common source.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18324493     DOI: 10.1080/13693780701742399

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  18 in total

1.  In vitro antifungal susceptibility of Sporothrix globosa isolates from Jilin Province, northeastern China: comparison of yeast and mycelial phases.

Authors:  Yang Song; Shanshan Li; Ying Shi; Lipei Zhao; Yu Cui; Lei Yao; Yu Zhen; Ruili Chen; Yan Cui
Journal:  Braz J Microbiol       Date:  2020-06-17       Impact factor: 2.476

2.  Increase in virulence of Sporothrix brasiliensis over five years in a patient with chronic disseminated sporotrichosis.

Authors:  Dayvison F S Freitas; Suelen S Santos; Rodrigo Almeida-Paes; Manoel M E de Oliveira; Antonio C F do Valle; Maria Clara Gutierrez-Galhardo; Rosely M Zancopé-Oliveira; Joshua D Nosanchuk
Journal:  Virulence       Date:  2015       Impact factor: 5.882

3.  Multicenter, International Study of MIC/MEC Distributions for Definition of Epidemiological Cutoff Values for Sporothrix Species Identified by Molecular Methods.

Authors:  A Espinel-Ingroff; D P B Abreu; R Almeida-Paes; R S N Brilhante; A Chakrabarti; A Chowdhary; F Hagen; S Córdoba; G M Gonzalez; N P Govender; J Guarro; E M Johnson; S E Kidd; S A Pereira; A M Rodrigues; S Rozental; M W Szeszs; R Ballesté Alaniz; A Bonifaz; L X Bonfietti; L P Borba-Santos; J Capilla; A L Colombo; M Dolande; M G Isla; M S C Melhem; A C Mesa-Arango; M M E Oliveira; M M Panizo; Z Pires de Camargo; R M Zancope-Oliveira; J F Meis; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

4.  Phenotypic and molecular identification of Sporothrix isolates from an epidemic area of sporotrichosis in Brazil.

Authors:  Manoel Marques Evangelista Oliveira; Rodrigo Almeida-Paes; Mauro Medeiros Muniz; Maria Clara Gutierrez-Galhardo; Rosely Maria Zancope-Oliveira
Journal:  Mycopathologia       Date:  2011-06-24       Impact factor: 2.574

Review 5.  Successful Treatment of Canine Sporotrichosis with Terbinafine: Case Reports and Literature Review.

Authors:  Paula Gonçalves Viana; Anna Barreto Fernandes Figueiredo; Isabella Dib Ferreira Gremião; Luisa Helena Monteiro de Miranda; Isabela Maria da Silva Antonio; Jéssica Sepulveda Boechat; Ana Caroline de Sá Machado; Manoel Marques Evangelista de Oliveira; Sandro Antonio Pereira
Journal:  Mycopathologia       Date:  2017-12-08       Impact factor: 2.574

Review 6.  Sporothrix schenckii and Sporotrichosis.

Authors:  Mônica Bastos de Lima Barros; Rodrigo de Almeida Paes; Armando Oliveira Schubach
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

7.  Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis.

Authors:  Glaucia Francesconi; Antonio Carlos Francesconi do Valle; Sonia Lambert Passos; Mônica Bastos de Lima Barros; Rodrigo de Almeida Paes; André Luiz Land Curi; José Liporage; Cássio Ferreira Porto; Maria Clara Gutierrez Galhardo
Journal:  Mycopathologia       Date:  2010-11-21       Impact factor: 2.574

8.  Phenotypic and molecular characterisation of Sporothrix globosa of diverse origin from India.

Authors:  Shivaprakash M Rudramurthy; Shamanth A Shankarnarayan; Basavaraj M Hemashetter; Santwana Verma; Smriti Chauhan; Reema Nath; Jayanthi Savio; Malini Capoor; Harsimran Kaur; Anup K Ghosh; Arunaloke Chakrabarti
Journal:  Braz J Microbiol       Date:  2020-07-30       Impact factor: 2.476

9.  Biosynthesis and functions of a melanoid pigment produced by species of the sporothrix complex in the presence of L-tyrosine.

Authors:  Rodrigo Almeida-Paes; Susana Frases; Glauber de Sousa Araújo; Manoel Marques Evangelista de Oliveira; Gary J Gerfen; Joshua D Nosanchuk; Rosely Maria Zancopé-Oliveira
Journal:  Appl Environ Microbiol       Date:  2012-10-05       Impact factor: 4.792

10.  Efficacy of posaconazole in murine experimental sporotrichosis.

Authors:  Fabiola Fernández-Silva; Javier Capilla; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.